Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers - A meta-analysis

Journal of Inflammation (United Kingdom)

Volumn 10, Issue 1, 2013, Pages

  Baessler, Aaron ^a   Nadeem, Rashid ^b   Harvey, Michael ^a   Madbouly, Essam ^b   Younus, Amna ^c   Sajid, Hassan ^d   Naseem, Jawed ^e   Asif, Asma ^a   Bawaadam, Hasnain ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b James A Lovell Federal Health Care Center   (United States)

^c BAHRIA UNIVERSITY   (Pakistan)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

AHI (apnea hypopnea index); BMI (body mass index); CPAP (continuous positive airway pressure); CRP (C reactive protein); IL 6 (interleukin 6); ODI (oxygen desaturation index); OSA (obstructive sleep apnea); TNF (tumor necrosis factor alpha)

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

APNEA HYPOPNEA INDEX; ARTICLE; BLOOD LEVEL; DATA ANALYSIS; HUMAN; META ANALYSIS; POSITIVE END EXPIRATORY PRESSURE; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EQUUS ASINUS;

EID: 84875182830     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-10-13     Document Type: Article

References (82)

1. The occurrence of sleep-disordered breathing among middle-aged adults. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S, N Engl J Med 1993 32 1230 1235
2. Risk factors for obstructive sleep apnea in adults. Young T, Skatrud J, Peppard PE, JAMA 2004 291 2013 2016 10.1001/jama.291.16.2013 15113821
3. The sleep apnea syndromes. Guilleminault C, Tilkian A, Dement WC, Annu Rev Med 1976 27 465 484 10.1146/annurev.me.27.020176.002341 180875
4. Sympathetic neural mechanisms in obstructive sleep apnea. Somers VK, Dyken ME, Clary MP, Abboud FM, J Clin Invest 1995 96 1897 1904 10.1172/JCI118235 7560081
5. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Kato M, Roberts-Thomson P, Phillips BG, Circulation 2000 102 2607 2610 10.1161/01.CIR.102.21.2607 11085964
6. Atherosclerosis: an inflammatory disease. Ross R, N Engl J Med 1999 340 115 126 10.1056/NEJM199901143400207 9887164
7. Atherosclerosis: the road ahead. Glass CK, Witztum JL, Cell 2001 104 503 516 10.1016/S0092-8674(01)00238-0 11239408
8. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Nieto FJ, Young TB, Lind BK, Sleep Heart Health. JAMA 2000 283 1829 1836
9. Prospective study of the association between sleep-disordered breathing and hypertension. Peppard PE, Young T, Palta M, N Engl J Med 2000 342 1378 1384 10.1056/NEJM200005113421901 10805822
10. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O'Connor GT, Boland LL, Schwartz JE, Samet JM, Am J Respir Crit Care Med 2001 163 19 25 10.1164/ajrccm.163.1.2001008 11208620
11. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J, Am J Respir Crit Care Med 2002 166 159 165 10.1164/rccm.2105124 12119227
12. Obstructive sleep apnea during sleep is associated with peripheral vasoconstriction. Imadojemu VA, Gleeson K, Gray KS, Sinoway LI, Leuenberger UA, Am J Respir Crit Care Med 2002 165 61 66 10.1164/ajrccm.165.1.2009062 11779731
13. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Sajkov D, Wang T, Saunders NA, Bune AJ, McEvoy RD, Am J Respir Crit Care Med 2002 166 152 158
14. Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Amin RS, Kimball TR, Bean JA, Jeffries JL, Willging JP, Cotton RT, Witt SA, Glascock BJ, Daniels SR, Am J Respir Crit Care Med 2002 165 1395 1399 10.1164/rccm.2105118 12016102
15. Inflammation in the uvula mucosa of patients with obstructive sleep apnea. Sekosan M, Zakkar M, Wenig BL, Olopade CO, Rubenstein I, Laryngoscope 1996 106 1018 1020 10.1097/00005537-199608000-00021 8699893
16. Images in allergy and immunology: obstructive sleep apnea syndrome and inflammation. Bergeron C, Kimoff J, Hamid Q, J Allergy Clin Immunol 2005 116 1393 1396 10.1016/j.jaci.2005.10.008 16337480
17. Vibration enhances interleukin-8 release in a cell model of snoring induced airway inflammation. Puig F, Rico F, Almendros I, Montserrat JM, Navajas D, Farre R, Sleep 2005 28 1312 1316 16295217
18. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Circulation 2003 107 1129 1134 10.1161/01.CIR.0000052627.99976.18 12615790
19. Elevated C-reactive protein in patients with obstructive sleep apnea. Shamsuzzaman ASM, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK, Circulation 2002 105 2462 2464 10.1161/01.CIR.0000018948.95175.03 12034649
20. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B, Int Heart J 2005 46 801 809 10.1536/ihj.46.801 16272771
21. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Ursavaş A, Karadaǧ M, Rodoplu E, Yilmaztepe A, Oral HB, Gözü RO, Respiration 2007 74 525 532 10.1159/000097770 17148932
22. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. von Känel R, Loredo JS, Ancoli-Israel S, Mills PJ, Natarajan L, Dimsdale JE, Chest 2007 131 733 739 10.1378/chest.06-2006 17356087
23. C-reactive protein is associated with sleep disordered breathing independent of adiposity. Punjabi NM, Beamer BA, Sleep 2007 30 29 34 17310862
24. Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness. de la Pena Bravo M, Serpero LD, Barcelo A, Sleep Breath 2007 11 177 185 10.1007/s11325-007-0100-7 17279423
25. Elevated production of tumor necrosis factor-α by monocytes in patients with obstructive sleep apnea syndrome. Minoguchi K, Tazaki T, Yokoe T, Chest 2004 126 1473 1479 10.1378/chest.126.5.1473 15539715
26. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Ciftci TU, Korturk O, Bukan N, Cytokine 2004 28 87 91 10.1016/j.cyto.2004.07.003 15381186
27. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP, J Clin Endocrinol Metab 1997 82 1313 1316 10.1210/jc.82.5.1313 9141509
28. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP, J Endocrinol Metab 2000 85 1151 1158 10.1210/jc.85.3.1151
29. The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome. Liu H, Liu J, Xiong S, Shen G, Zhang Z, Xu Y, J Tongji Med Univ 2000 20 200 202 10.1007/BF02886988 11215046
30. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Barceló A, Barbé F, Llompart E, Mayoralas LR, Ladaria A, Bosch M, Am J Respir Crit Care Med 2004 117 118 121
31. C-reactive protein and sleep-disordered breathing. Guilleminault C, Kirisoglu C, Ohayon MM, Sleep 2004 27 1507 1511 15683141
32. Acute phase response of human hepatocyte: regulation of acute-phase protein synthesis by interleukin-6. Castell J, Gomez-Lechion M, David M, Hepatology 1990 12 1179 1186 10.1002/hep.1840120517 1699862
33. Obesity and erythrocyte sedimentation rates. Pasulka P, Bristian BR, Blackburn GL, Ann Intern Med 1985 103 304 4014915
34. Raised interleukin-6 levels in obese patients. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A, Obes Res 2000 8 673 675 10.1038/oby.2000.86 11225716
35. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Meier-Ewert HK, Ridker PM, Rifai N, Clin Chem 2001 47 426 430 11238292
36. C-reactive protein: risk marker or mediator in atherothrombosis? Jialal I, Devaraj S, Venugopal SK, Hypertension 2004 44 6 11 10.1161/01.HYP.0000130484. 20501.df 15148294
37. Infl ammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Calabro P, Willerson JT, Yeh ET, Circulation 2003 108 1930 1932 10.1161/01.CIR.0000096055.62724.C5 14530191
38. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Devaraj S, Xu DY, Jialal I, Circulation 2003 107 398 404 10.1161/01.CIR.0000052617.91920.FD 12551862
39. C-reactive protein promotes monocyte chemoattractant protein-I-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ, Circulation 2004 109 2566 2571 10.1161/01.CIR.0000131160.94926.6E 15136507
40. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Fichlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM, Eur Heart J 2004 25 1412 1418 10.1016/j.ehj.2004.06. 026 15321699
41. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Ridker PM, Circulation 2001 103 1813 1818 10.1161/01.CIR.103.13.1813 11282915
42. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Danesh J, Whincup P, Walker M, BMJ 2000 321 199 204 10.1136/bmj.321.7255.199 10903648
43. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Ridker PM, Circulation 2003 107 363 369 10.1161/01.CIR.0000053730.47739.3C 12551853
44. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. Lindahl B, Toss H, Siegbahn A, N Engl J Med 2000 343 1139 1147 10.1056/NEJM200010193431602 11036119
45. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Ridker PM, Rifai N, Pfeffer MA, Circulation 1999 100 230 235 10.1161/01.CIR.100.3.230 10411845
46. kumari M, Humphries SE, Mohamed-Ali V. Infl ammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Yudkin JS, Atherosclerosis 2000 148 209 214 10.1016/S0021-9150(99)00463-3 10657556
47. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Harris TB, Ferruci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Am J Med 1999 106 506 512 10.1016/S0002-9343(99)00066-2 10335721
48. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Aderka D, Cytokine Growth Factor Rev 1996 7 231 240 10.1016/S1359-6101(96)00026-3 8971478
49. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Brockhaus M, Schoenfeld H, Schlaeger E, Hunziker W, Lesslauer W, Loetscher H, Proc Natl Acad Sci USA 1990 87 3127 3131 10.1073/pnas.87.8.3127 2158104
50. Circadian interleukin-6 secretion and quantity and depth of sleep. Vgontzas AN, Papanicolaou DA, Bixler EO, J Clin Endocrinol Metab 1999 84 2603 2607 10.1210/jc.84.8.2603 10443646
51. Contributions of hypoxia and respiratory disturbance index to sympathetic activation and blood pressure in obstructive sleep apnea syndrome. Peled N, Greenberg A, Pillar G, Am J Hypertens 1998 11 1284 1289 10.1016/S0895-7061(98) 00159-9 9832170
52. The art and science of continuous positive airway pressure therapy in obstructive sleep apnea. Malhotra A, Ayas NT, Epstein LJ, Curr Opin Pulm Med 2000 6 490 495 10.1097/00063198-200011000-00005 11100958
53. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Patel SR, White DP, Malhotra A, Arch Intern Med 2003 163 565 571 10.1001/archinte.163.5.565 12622603
54. Quality of life in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure-a prospective study. D'Ambrosio C, Bowman T, Mohsenin V, Chest 1999 115 123 129 10.1378/chest.115.1.123 9925072
55. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Milleron O, Pilliere R, Foucher A, Eur Heart 2004 25 728 734 10.1016/j.ehj.2004.02.008
56. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB, Evidence base Medicine-How to practice and teach EBM Oxford: Churchill Livingstone 2 2000 173 175
57. Estimating the mean and variance from the median, range, and the size of a sample. Hozo SP, Djulbegovic B, Hozo I, BMC medical research methodology 2005 5 13 10.1186/1471-2288-5-13 15840177
58. Fixed and autoadjusting continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep apnea. Patruno V, Aiolfi S, Costantino G, Murgia R, Selmi C, Malliani A, Montano N, Chest 2007 131 5 1393 1399 10.1378/chest.06-2192 17494789
59. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. Phillips CL, Yang Q, Williams A, Roth M, Yee BJ, Hedner JA, Berend N, Grunstein RR, J Sleep Res 2007 16 2 217 225 10.1111/j.1365-2869.2007.00589.x 17542952
60. Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Tamaki S, Yamauchi M, Fukuoka A, Makinodan K, Koyama N, Tomoda K, Yoshikawa M, Kimura H, Intern Med 2009 48 15 1255 1262 10.2169/internalmedicine.48.2366 19652426
61. C-reactive protein evolution in obstructive sleep apnoea patients under CPAP therapy. Schiza SE, Bouloukaki I, Mermigkis C, Panagou P, Tzanakis N, Moniaki V, Tzortzaki E, Siafakas NM, Eur J Clin Invest 2010 40 11 968 975 10.1111/j.1365-2362.2010.02348.x 20629709
62. CRP evolution pattern in CPAP-treated obstructive sleep apnea patients. Does gender play a role? Mermigkis C, Bouloukaki I, Mermigkis D, Kallergis E, Mavroudi E, Varouchakis G, Tzortzaki E, Siafakas N, Schiza SE, Sleep Breath 2012 16 3 813 819 10.1007/s11325-011-0580-3 21881894
63. Continuous positive airway pressure therapy improves hypoadiponectinemia in severe obese men with obstructive sleep apnea without changes in insulin resistance. Carniero G, Togeiro SM, Ribeiro-Filho FF, Truksinas E, Ribeiro AB, Zanella MT, Tufik S, Metab Syndr Relat Disord 2009 7 6 537 542 10.1089/met.2009.0019 19558268
64. The effects of nasal continuous positive airway pressure on vascular functions and serum cardiovascular risk factors in obstructive sleep apnea syndrome. Chung S, Yoon IY, Lee CH, Kim JW, Sleep Breath 2011 15 1 76 81
65. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M, Francis A, Bohonis S, Zeqlinski M, Kirkpatrick ID, Sharma S, Jassal DS, Chest 2012 141 3 674 681 10.1378/chest.11-0615 21835901
66. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Dorkova Z, Petrasova D, Molcayiova A, Popovnakova M, Tkacova R, Chest 2008 134 4 686 692 10.1378/chest.08-0556 18625666
67. Resistin levels in patients with obstructive sleep apnoea syndrome-the link to subclinical inflammation? Harsch IA, Koebnick C, Wallaschofski H, Schahin SP, Hahn EG, Ficker JH, Lohmann T, Konturek PC, Med Sci Monit 2004 10 9 R510 5 15328483
68. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Iesato K, Tatsumi K, Saibara T, Nakamura A, Terada J, Tada Y, Sakao S, Tanabe N, Takiguchi Y, Kuriyama T, Circ J 2007 71 8 1293 8 10.1253/circj.71.1293 17652898
69. Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Ishida K, Kato M, Kato Y, Yanagihara K, Kinugasa Y, Kotani K, Igawa O, Hisatome I, Shigemasa C, Somers VK, Chest 2009 136 1 125 129 10.1378/chest.08-1431 19255295
70. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, McNicholas WT, Thorax 2007 62 6 509 514 10.1136/thx.2006.066720 17251313
71. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D, Chest 2007 132 3 843 851 10.1378/chest.07-0074 17573492
72. Effects of obstructive sleep apnea and its treatment on cardiovascular risk in CAD patients. Zhao Q, Liu ZH, Zhao ZH, Luo Q, McEvoy RD, Zhang HL, Wang Y, Respir Med 2011 105 10 1557 1564 10.1016/j.rmed.2011.05.010 21646006
73. CPAP decreases plasma levels of soluble tumour necrosis factor-alpha receptor 1 in obstructive sleep apnoea. Arias MA, García-Río F, Alonso-Fernández A, Hernanz A, Hidalgo R, Martínez-Mateo V, Bartolomé S, Rodríguez-Padial L, Eur Respir J 2008 32 4 1009 1015 10.1183/09031936.00007008 18508832
74. Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Guasti L, Marino F, Cosentino M, Maroni L, Maresca AM, Colombo F, Maio RC, Castiglioni L, Saporiti F, Loraschi A, Gaudio G, Bernasconi A, Laurita E, Grandi AM, Venco A, Sleep Breath 2011 15 1 3 11 10.1007/s11325-009-0315-x 19924457
75. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Ryan S, Taylor CT, McNicholas WT, Circulation 2005 112 17 2660 2667 10.1161/CIRCULATIONAHA.105.556746 16246965
76. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Ryan S, Taylor CT, McNicholas WT, Am J Respir Crit Care Med 2006 174 7 824 830 10.1164/rccm.200601-066OC 16840748
77. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Steiropoulos P, Kotsianidis I, Nena E, Tsara V, Gounari E, Hatzizisi O, Kyriazis G, Christaki P, Froudarakis M, Bouros D, Sleep 2009 32 4 537 543 19413148
78. Selective effects of CPAP on sleep apnoea-associated manifestations. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Collins B, Basta M, Pejovic S, Chrousos GP, Eur J Clin Invest 2008 38 8 585 595 10.1111/j.1365-2362.2008.01984. x 18627419
79. Day-night variations of serum interleukin-6 in patients with severe obstructive sleep apnea syndrome before and after continuous positive airway pressure (CPAP). Burioka N, Miyata M, Fukuoka Y, Endo M, Shimizu E, Chronobiol Int 2008 25 5 827 834 10.1080/07420520802384101 18780208
80. Quantification of circulating cell-free DNA in the serum of patients with obstructive sleep apnea-hypopnea syndrome. Ye L, Ma GH, Chen L, Li M, Liu JL, Yang K, Li QY, Li N, Wan HY, Lung 2010 188 6 469 474 10.1007/s00408-010-9253-4 20668869
81. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep disordered breathing. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P, Sleep Med 2007 8 1 12 17 10.1016/j.sleep.2006.06.014 17157064
82. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomized controlled trial. Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Crosthwaite N, Craig S, Siccoli MM, Davies RJ, Stradling JR, Thorax 2009 64 1 67 73 18786982